Recurrent spontaneous pneumothorax under nintedanib treatment in ınterstitial lung disease associated with systemic sclerosis.
Sarcoidosis vasculitis and diffuse lung diseases · 20.12.2023 · 40 (4) · e2023044-e2023044
DOI: 10.36141/svdld.v40i4.14716 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sarcoidosis vasculitis and diffuse lung diseases, erschienen am 20.12.2023. Verfasst von Abdurrahman Soner Şenel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Erciyes University of Rheumatology /Internal medicine Kayseri, Turkey. drsonersenel@gmail.com. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Interstitial lung disease (ILD) is a common complication that can develop during the course of systemic sclerosis (SSc). Nindetanib is an antifibrotic drug approved for the treatment of systemic sclerosis-associated interstitial lung disease. Although there is an insufficient data on the development of pneumothorax, the safety of Nintedanib treatment is also uncertain. We observed recurrent resistant pneumothorax under nintedanib treatment in a patient with systemic sclerosis-associated interstitial lung disease. Nintedanib use may increase the risk of developing refractory pneumothorax. Ssc patients who are started on nintedanib should be followed carefully for pneumothorax.
Schlagwörter
Autor:innen und Institutionen
- Department of Erciyes University of Rheumatology /Internal medicine Kayseri, Turkey. drsonersenel@gmail.com.
- Department of Erciyes University of Rheumatology /Internal medicine Kayseri, Turkey. tugba_dr_@hotmail.com.
- Department of Erciyes University of Rheumatology /Internal medicine Kayseri, Turkey. melihkiziltepe@erciyes.edu.tr.
- Department of Erciyes University of Rheumatology /Internal medicine Kayseri, Turkey. dr_eoguz@hotmail.com.
- Department of Erciyes University of Pulmonology , Kayseri, Turkey . ntutar@erciyes.edu.tr.
Zitieren
APA
Şenel, A. S., Kahraman Denizhan, T., Kızıltepe, M., Oğuz Kökoğlu, E., & Tutar, N. (2023). Recurrent spontaneous pneumothorax under nintedanib treatment in ınterstitial lung disease associated with systemic sclerosis. Sarcoidosis vasculitis and diffuse lung diseases, 40(4), e2023044-e2023044. https://doi.org/10.36141/svdld.v40i4.14716
Vancouver
Şenel AS, Kahraman Denizhan T, Kızıltepe M, Oğuz Kökoğlu E, Tutar N. Recurrent spontaneous pneumothorax under nintedanib treatment in ınterstitial lung disease associated with systemic sclerosis. Sarcoidosis vasculitis and diffuse lung diseases. 2023;40(4):e2023044-e2023044. doi:10.36141/svdld.v40i4.14716
BibTeX
@article{enel2023,
author = {Şenel, Abdurrahman Soner and Kahraman Denizhan, Tuğba and Kızıltepe, Melih and Oğuz Kökoğlu, Emel and Tutar, Nuri},
title = {Recurrent spontaneous pneumothorax under nintedanib treatment in ınterstitial lung disease associated with systemic sclerosis},
journal = {Sarcoidosis vasculitis and diffuse lung diseases},
year = {2023},
volume = {40},
number = {4},
pages = {e2023044--e2023044},
doi = {10.36141/svdld.v40i4.14716}
}
EUVIMED